Mesoblast Achieves Major Milestone in Pivotal Phase 3 Chronic Low Back Pain Trial
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast (ASX:MSB) has completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, marking a major milestone as the company moves towards a potentially important clinical readout in 2027. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. The MSB-DR004 trial has now randomised and treated 350 patient…
Mesoblast Achieves Major Milestone in Pivotal Phase 3 Chronic Low Back Pain Trial
Mesoblast Limited (ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced the completion of patient treatment in its pivotal randomised controlled Phase 3 trial, MSB-DR004. The company, which develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions, is evaluating rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory c…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
